secwatch / observer
8-K filed October 16, 2025, 7:59 PM ET ticker AKTX CIK 0001541157
other confidence high sentiment neutral materiality 0.60

Akari prices $2.5M registered direct offering of ADSs and warrants at $0.80/unit

Akari Therapeutics Plc

Key facts

Extracted from this filing and checked against the source text.

Equity Issuances SEC 8-K Item 3.02/3.03 confidence 0.95

Akari Therapeutics Plc issued 3,125,000 ADSs each representing 2,000 ordinary shares of unit to institutional investors for $0.80 per combined ADS and accompanying warrants, aggregate gross proceeds approximately $2.5 million.

Security
unit
Shares
3,125,000 ADSs each representing 2,000 ordinary shares
Purchaser
institutional investors
Consideration
$0.80 per combined ADS and accompanying warrants, aggregate gross proceeds approximately $2.5 million
Exact text from the filing
E Warrants, the “Warrants”), which are being issued in a concurrent private placement. The combined purchase price per each ADS and accompanying Warrants sold in the Offering is $0.80. The aggregate gross proceeds from the Offering are expected to be approximately $2.5 million, excluding any proceeds from any future exercises of Warrants. The Offering
View on SEC.gov
Equity Issuances SEC 8-K Item 3.02/3.03 confidence 0.9

Akari Therapeutics Plc issued Placement Agent warrants to purchase up to 125,000 ADSs of warrant to Placement Agent for Issued as compensation for placement agent services; exercise price $1.00 per share; 5-year term.

Security
warrant
Shares
Placement Agent warrants to purchase up to 125,000 ADSs
Purchaser
Placement Agent
Consideration
Issued as compensation for placement agent services; exercise price $1.00 per share; 5-year term
Exact text from the filing
The Placement Agent or its designees will also receive warrants (the “Placement Agent Warrants”) on substantially the same terms as the Series E Warrants in an amount equal to 4.0% of the aggregate number of ADSs sold in the Offering, or Placement Agent warrants to purchase up to 125,000 ADSs, at an exercise price of $1.00 per share and will have a 5-year term from the commencement of sales of the Offering.
View on SEC.gov
Equity Issuances SEC 8-K Item 3.02/3.03 confidence 0.95

Akari Therapeutics Plc issued Series E warrants to purchase up to 3,125,000 ADSs and Series F warrants to purchase up to 3,125,000 ADSs of warrant to institutional investors for Issued as part of unit with ADS at $0.80 per combined unit; exercise price $0.98 per share.

Security
warrant
Shares
Series E warrants to purchase up to 3,125,000 ADSs and Series F warrants to purchase up to 3,125,000 ADSs
Purchaser
institutional investors
Consideration
Issued as part of unit with ADS at $0.80 per combined unit; exercise price $0.98 per share
Exact text from the filing
E Warrants, the “Warrants”), which are being issued in a concurrent private placement. The combined purchase price per each ADS and accompanying Warrants sold in the Offering is $0.80. The aggregate gross proceeds from the Offering are expected to be approximately $2.5 million, excluding any proceeds from any future exercises of Warrants. The Offering
View on SEC.gov

Browse all equity issuances →

Akari Therapeutics Plc filing history →

Source: SEC EDGAR
accession 0001493152-25-018269
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.